Ophthalmology

The findings support treating eyes with the condition before they progress to proliferative diabetic retinopathy.

The specialty is on the precipice of advancement. What gets it over the hurdle?

In a study presented at ASRS 2020, investigators find an improvement in DRSS is not correlated with a change in best corrected visual acuity.

The implementation of teleretinal screening could improve clinic workflow.

Using the 4 JAMA benchmarks, investigators do not find any online articles that are entirely accurate and accountable.

The findings of the study highlight the importance of screening eye exams from index diagnosis.

Steroids are often prescribed for diabetic macular edema following ineffectiveness of laser photocoagulation and anti-VEGF.

The findings demonstrate the importance of providers to manage diabetes, diabetic retinopathy, and mental illness comorbidities.

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

Top websites for macular degeneration content do not necessarily have better quality information or readability.

In data presented virtually during the ASRS 2020 meeting, investigators find X-82 is non inferior in visual acuity outcomes.

The addition of oral zeaxanthin reduces the risk of subfoveal choroidal neovascularization development compared to previously published studies.

A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.

How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

A look at how primary care patients begin to present with diabetic retinopathy risk.

New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

The ongoing COVID-19 pandemic has forced several ophthalmologists to cancel appointments with patients who might be at a risk of developing sight-threatening illnesses.

Cataracts and diabetic retinopathy are the 2 leading causes of acquired blindness worldwide.

Intraclass correlation coefficients for short-term variability among the 7 periods during the day ranged from 0.52 in the morning period to 0.66 in the early period and long-term ICCs ranged from 0.29 at night to 0.51 during the late period.

For the EMB treatment group, 65.6% of participants (n = 160) lost fewer than 15 ETDRS letters, while 86.6% (n = 103) in the ranibizumab group lost fewer than 15 ETDRS letters.

In the multivariate analyses, particulate matter of 2.5 μm or less (PM2.5) was linked with dry eye metrics when adjusted for demographic characteristics, comorbidities, medications, and interaction variables.

New research shows patients with both conditions have greater levels of particular cytokines and metabolic proteins.

A new analysis of more than 260 children is shedding light on associations between blood pressure and ophthalmic issues later in life.

After promising early findings for the investigative therapy in a rare form of blindness, investigators turn to the next phase.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.

Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.